IMRX
Immuneering Corp
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Immuneering Corp
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Immuneering has 3 disclosed suppliers and 1 disclosed customer in SEC filings.
Immuneering Corp
3.69
SentenceIn August 2025, we announced a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982), which intends to support the evaluation of atebimetinib in combination with olomorasib in a planned clinical trial of patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have progressed on prior therapy.
SentenceIn February 2025, we announced entry into a clinical supply agreement with Regeneron Pharmaceuticals for its anti-PD-1 therapy, Libtayo® (cemiplimab), which intends to support the evaluation of atebimetinib in combination with Libtayo in a planned clinical trial of patients with unresectable or metastatic RAS-mutant non-small cell lung cancer.
SentenceBioArkive was a San Diego based contract research organization that previously provided preclinical research services and biosample storage to us and other biotechnology companies.
IMRX 10-Kaccession 0001790340-26-000042
SentenceThe September 2025 Purchase Agreement provided for the sale and issuance by us to Aventis of an aggregate of 2,708,559 shares of our common stock at a purchase price of $9.23 per share.
IMRX 10-Kaccession 0001790340-26-000042
Linked news
Expected move
No implied move.